Technosphere® Insulin Inhalation Powder

DRUG5 trials

Sponsors

Mannkind Corporation

Conditions

Diabetes Mellitus: Type 1Diabetes Type 2Diabetes, Type 1Diabetes, Type 2Healthy VolunteersType 2 Diabetes

Phase 1

Pharmacokinetic Study in Healthy Volunteers

CompletedNCT01365117

Mannkind CorporationHealthy Volunteers

Start: 2011-01-31End: 2011-04-30Updated: 2012-06-14

Phase 2

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

CompletedNCT00662857

Mannkind CorporationDiabetes Mellitus: Type 1

Start: 2008-04-30End: 2008-12-31Updated: 2014-10-16

Phase 3

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

CompletedNCT00308737

Mannkind CorporationDiabetes, Type 1, Diabetes, Type 2

Start: 2005-06-30End: 2008-10-31Updated: 2014-10-16

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

CompletedNCT00309244

Mannkind CorporationDiabetes Type 2

Start: 2006-02-28End: 2008-09-30Updated: 2014-10-16

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

TerminatedNCT01196104

Mannkind CorporationType 2 Diabetes

Start: 2010-09-30End: 2012-03-31Updated: 2014-10-30

Related Papers

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin

BMJ Open Diabetes Research & Care2016-08-016 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.

2010-06-0168 citations